<DOC>
	<DOCNO>NCT01970475</DOCNO>
	<brief_summary>The purpose study compare effectiveness safety ABP 501 adalimumab ( HUMIRA® ) adult moderate severe rheumatoid arthritis ( RA ) inadequate response methotrexate ( MTX ) .</brief_summary>
	<brief_title>Efficacy Safety Study ABP 501 Compared Adalimumab Subjects With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Men woman ≥ 18 ≤ 80 year old 2 . Subjects must diagnose rheumatoid arthritis least 3 month baseline 3 . Active RA define ≥ 6 swollen joint ≥ 6 tender joint screen baseline 4 . Subjects must take MTX ≥ 12 consecutive week stable dose 7.5 25 mg/week &gt; 8 week prior receive study drug willing remain stable dose throughout study 5 . Subject known history active tuberculosis 1 . Class IV RA , Felty 's syndrome history prosthetic native joint infection 2 . Major chronic inflammatory disease connective tissue disease RA , exception secondary Sjögren 's syndrome 3 . Prior use 2 biologic therapy RA 4 . Previous receipt HUMIRA® ( adalimumab ) biosimilar adalimumab 5 . Ongoing use prohibit treatment Other Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatoid</keyword>
</DOC>